5 EASY FACTS ABOUT ABBV-744 COMBINATION THERAPY WITH CHEMOTHERAPY DESCRIBED

In Segment C, members will get ABBV-744 and oral navitoclax. In Phase D, individuals will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until disorder progression or even the individuals are unable to tolerate the study drugs.There might be greater treatment load for participants Within this trial in comparison with their sta